Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson Seite 1

21.11.2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that a patient who participated in the ... Seite 1

Related Keywords

Romania ,Israel ,Motti Farbstein ,Drug Administration ,Data Monitoring Committee ,European Medicines Agency ,Can Fite Phase ,Orphan Drug ,Fast Track Status ,Independent Data Monitoring Committee ,Can Fite ,